Related Experiment Video

Updated: May 3, 2026

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.0K

Risk factors for behavioral abnormalities in mild cognitive impairment and mild Alzheimer's disease

Liana G Apostolova1, Li Jie Di, Erin L Duffy

  • 1Department of Neurology, UCLA, Los Angeles, Calif., USA.

Dementia and Geriatric Cognitive Disorders
|February 1, 2014
PubMed
Abstract

Insights

Behavioral symptoms are common in mild cognitive impairment (MCI) and Alzheimer's disease (AD). Younger age, male gender, and functional impairment are linked to more symptoms, while marital status, education, and race affect specific behaviors.

Area of Science:

  • Neuroscience
  • Gerontology
  • Psychiatry

Background:

  • Behavioral symptoms are frequently observed in individuals with mild cognitive impairment (MCI) and Alzheimer's disease (AD).
  • Understanding these symptoms is crucial for effective patient care and management in neurodegenerative conditions.

Purpose of the Study:

  • To identify factors associated with the presence and type of behavioral symptoms in MCI and mild AD.
  • To compare behavioral symptom prevalence between amnestic and nonamnestic MCI subtypes.

Main Methods:

  • Analysis of Neuropsychiatric Inventory Questionnaire data from 3,456 MCI and 2,641 mild AD participants in the National Alzheimer's Coordinating Center database.
  • Factor analysis and logistic regression were employed to assess the influence of demographic, clinical, and functional variables on behavioral symptoms.
  • Comparison of behavioral symptom prevalence between amnestic and nonamnestic MCI groups.

Main Results:

  • Four distinct behavioral symptom factors emerged: affective, distress/tension, impulse control, and psychotic behaviors.
  • Male gender, younger age, and greater functional impairment were significantly associated with a higher prevalence of overall behavioral symptoms.
  • Marital status, education level, and race were linked to specific behavioral symptom clusters, with Caucasians showing more affective behaviors.

Conclusions:

  • Younger age, male sex, and significant functional impairment are key predictors of increased behavioral abnormalities in MCI and mild AD.
  • Demographic factors like marital status, education, and race play a role in the manifestation of specific behavioral symptoms.
  • Findings highlight the complex interplay of factors contributing to behavioral symptoms in cognitive decline, informing targeted interventions.

More Related Videos

A Behavioral Test Battery for the Repeated Assessment of Motor Skills, Mood, and Cognition in Mice07:18

A Behavioral Test Battery for the Repeated Assessment of Motor Skills, Mood, and Cognition in Mice

Published on: March 2, 2019

18.9K
Analysis of Learning and Memory Ability in an Alzheimer's Disease Mouse Model using the Morris Water Maze07:07

Analysis of Learning and Memory Ability in an Alzheimer's Disease Mouse Model using the Morris Water Maze

Published on: October 29, 2019

21.0K

Related Concept Videos

Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
35
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
35
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
687
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K